Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials.
BACKGROUND
There are limited studies of stent thrombosis in the modern era of second-generation stents, high-pressure deployment, and current antithrombotic regimens.


RESULTS
Six recently completed coronary stent trials and associated nonrandomized registries that enrolled 6186 patients (6219 treated vessels) treated with >/=1 coronary stent followed by antiplatelet therapy with aspirin and ticlopidine were pooled for this analysis. Within 30 days, clinical stent thrombosis developed in 53 patients (0.9%). The variables most significantly associated with the probability of stent thrombosis were persistent dissection NHLBI grade B or higher after stenting (OR, 3.7; 95% CI, 1.9 to 7.7), total stent length (OR, 1.3; 95% CI, 1.2 to 1.5 per 10 mm), and final minimal lumen diameter within the stent (OR, 0.4; 95% CI, 0.2 to 0.7 per 1 mm). Stent thrombosis was documented by angiography in 45 patients (0.7%). Clinical consequences of angiographic stent thrombosis included 64.4% incidence of death or myocardial infarction at the time of stent thrombosis and 8.9% 6-month mortality.


CONCLUSIONS
Stent thrombosis occurred in <1.0% of patients undergoing stenting of native coronary artery lesions and receiving routine antiplatelet therapy with aspirin plus ticlopidine. Procedure-related variables of persistent dissection, total stent length, and final lumen diameter were significantly associated with the probability of stent thrombosis. Continued efforts to eliminate this complication are warranted given the serious clinical consequences.
Cutlip
D E
DE
University of Rochester Medical Center, Rochester, NY, USA.
Baim
D S
DS
Ho
K K
KK
Popma
J J
JJ
Lansky
A J
AJ
Cohen
D J
DJ
Carrozza
J P
JP
Chauhan
M S
MS
Rodriguez
O
O
Kuntz
R E
RE
D001241:Aspirin / Q000627:therapeutic use; D019917:Blood Vessel Prosthesis Implantation; D015984:Causality; D003327:Coronary Disease / Q000188:drug therapy / Q000601:surgery; D003328:Coronary Thrombosis / Q000453:epidemiology* / Q000401:mortality; D023381:Endpoint Determination; D005260:Female; D006083:Graft Occlusion, Vascular / Q000453:epidemiology* / Q000401:mortality; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009204:Myocardial Revascularization; D016017:Odds Ratio; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate; D013988:Ticlopidine / Q000627:therapeutic use; D016896:Treatment Outcome
D010975:Platelet Aggregation Inhibitors; D013988:Ticlopidine; D001241:Aspirin